Literature DB >> 30550780

CGRP Antibodies as Prophylaxis in Migraine.

Lars Edvinsson1.   

Abstract

Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30550780     DOI： 10.1016/j.cell.2018.11.049

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  11 in total

1.  Transcriptional Atlas of Intestinal Immune Cells Reveals that Neuropeptide α-CGRP Modulates Group 2 Innate Lymphoid Cell Responses.

Authors:  Heping Xu; Jiarui Ding; Caroline B M Porter; Antonia Wallrapp; Marcin Tabaka; Sai Ma; Shujie Fu; Xuanxuan Guo; Samantha J Riesenfeld; Chienwen Su; Danielle Dionne; Lan T Nguyen; Ariel Lefkovith; Orr Ashenberg; Patrick R Burkett; Hai Ning Shi; Orit Rozenblatt-Rosen; Daniel B Graham; Vijay K Kuchroo; Aviv Regev; Ramnik J Xavier
Journal:  Immunity       Date:  2019-10-15       Impact factor: 31.745

2.  Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.

Authors:  Simona Lattanzi; Francesco Brigo; Eugen Trinka; Fabrizio Vernieri; Tommaso Corradetti; Mauro Dobran; Mauro Silvestrini
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 3.  Devices for Episodic Migraine: Past, Present, and Future.

Authors:  David Moreno-Ajona; Jan Hoffmann; Simon Akerman
Journal:  Curr Pain Headache Rep       Date:  2022-02-11

4.  Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs).

Authors:  Paolo Martelletti; Lars Edvinsson; Messoud Ashina
Journal:  J Headache Pain       Date:  2019-05-23       Impact factor: 7.277

5.  Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men.

Authors:  Raffaele Ornello; Carlo Baraldi; Simona Guerzoni; Giorgio Lambru; Matteo Fuccaro; Bianca Raffaelli; Astrid Gendolla; Piero Barbanti; Cinzia Aurilia; Sabina Cevoli; Valentina Favoni; Fabrizio Vernieri; Claudia Altamura; Antonio Russo; Marcello Silvestro; Elisabetta Dalla Valle; Andrea Mancioli; Angelo Ranieri; Gennaro Alfieri; Nina Latysheva; Elena Filatova; Jamie Talbot; Shuli Cheng; Dagny Holle; Armin Scheffler; Tomáš Nežádal; Dana Čtrnáctá; Jitka Šípková; Zuzana Matoušová; Lucia Sette; Alfonsina Casalena; Maurizio Maddestra; Stefano Viola; Giannapia Affaitati; Maria Adele Giamberardino; Francesca Pistoia; Uwe Reuter; Simona Sacco
Journal:  Front Neurol       Date:  2021-12-16       Impact factor: 4.003

6.  Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index.

Authors:  Lucia Sette; Valeria Caponnetto; Raffaele Ornello; Tomáš Nežádal; Dana Čtrnáctá; Jitka Šípková; Zuzana Matoušová; Simona Sacco
Journal:  Front Neurol       Date:  2022-02-28       Impact factor: 4.003

7.  Insulin sensitizes neural and vascular TRPV1 receptors in the trigeminovascular system.

Authors:  Judit Rosta; Máté Tóth; Nadine Friedrich; Péter Sántha; Gábor Jancsó; Mária Dux
Journal:  J Headache Pain       Date:  2022-01-15       Impact factor: 7.277

8.  Environmental Enrichment and Its Benefits for Migraine: Dendritic Cell Extracellular Vesicles as an Effective Mimetic.

Authors:  Kae Myriam Pusic; Lisa Won; Richard Paul Kraig; Aya Darinka Pusic
Journal:  J Cell Immunol       Date:  2021

Review 9.  New Generation Gepants: Migraine Acute and Preventive Medications.

Authors:  David Moreno-Ajona; María Dolores Villar-Martínez; Peter J Goadsby
Journal:  J Clin Med       Date:  2022-03-16       Impact factor: 4.241

10.  New and sex-specific migraine susceptibility loci identified from a multiethnic genome-wide meta-analysis.

Authors:  Hélène Choquet; Jie Yin; Alice S Jacobson; Brandon H Horton; Thomas J Hoffmann; Eric Jorgenson; Andrew L Avins; Alice R Pressman
Journal:  Commun Biol       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.